We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Lundbeck disclosed Wednesday that two Phase III studies of the experimental drug idalopirdine in patients with Alzheimer's disease failed to demonstrate efficacy of the 5-HT6 antagonist.